Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...
SEB Equities upgraded Zealand Pharma (ZLDPF) to Buy from Hold with an DKK 850 price target Light Up your Portfolio with Spark:Easily identify ...
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
European shares jumped on Wednesday after Ukraine accepted the U.S.' proposal for a 30-day ceasefire with Russia, while ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback